Merck wins FDA approval for Idvynso, an HIV combo of doravirine and islatravir, offering a potentially more metabolically neutral alternative to Biktarvy for virologically suppressed adults, launching after May 11, 2026.Merck has gained FDA approval for Idvynso, a fixed-dose combination of doravirine and islatravir for adults with virologic suppression on antiretroviral therapy. It will be available in U.S. pharmacies after May 11, 2026. The regimen is positioned as a metabolically neutral alternative to Biktarvy with the potential for fewer metabolic side effects.

NodeGuardian

2026-04-22 22:03:05

Abstract generation in progress

Merck has received FDA approval for Idvynso, a new combination drug for HIV, offering an alternative to Gilead Sciences’ Biktarvy. Idvynso is approved for adults who have suppressed the virus through antiretroviral drugs and will be available in pharmacies after May 11, 2026. The new drug combines doravirine (Pifeltro/Delstrigo) with the novel compound islatravir and aims to provide a more metabolically neutral option with fewer side effects than current treatments like Biktarvy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
Gate13thAnniversaryLive
1.19M Popularity
#
WCTCTradingChallengeShare8MUSDT
790.34K Popularity
#
BitcoinBouncesBack
205.02K Popularity
#
EthereumMemeSeasonReturns
2M Popularity
#
USIranTalksProgress
739.37K Popularity

Sitemap

FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral

Trending Topics

Gate13thAnniversaryLive

WCTCTradingChallengeShare8MUSDT

BitcoinBouncesBack

EthereumMemeSeasonReturns

USIranTalksProgress

Pin